ABBV icon

AbbVie

227.23 USD
+2.29
1.02%
At close Updated Jun 5, 4:00 PM EDT
Pre-market
After hours
226.60
-0.63
0.28%
1 day
1.02%
5 days
5.56%
1 month
10.25%
3 months
-2.2%
6 months
0.51%
Year to date
-0.91%
1 year
21.21%
5 years
101.07%
10 years
261.72%
 

About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

Employees: 57,000

0
Funds holding %
of 8,076 funds
0
Positive news %
of 40 articles
Price charts implemented using Lightweight Charts™